RETRACTED: The Oncolytic Virus in Cancer Diagnosis and Treatment

Guodong Cao, Xiaobo He, Qiang Sun, Sihan Chen, Ke Wan, Xin Xu, Xudong Feng, Pengping Li, Qing Chen, Maoming XiongFrontiers in Oncology 2020 · DOI · OpenAlex

Abstract: Cancer remains a significant threat to global health. While traditional treatments like surgery, radiotherapy, and chemotherapy have improved survival rates, patients with advanced stages often face poor outcomes or prohibitive costs. Oncolytic viruses (OVs)—genetically engineered or naturally occurring viruses that selectively replicate in and destroy cancer cells while sparing healthy tissue—offer a promising new strategy. This review examines the clinical applications of OVs, including herpes simplex virus and adenovirus, and evaluates the future of oncolytic virotherapy by analyzing its current advantages and limitations.

Note on Document Status: This paper was officially RETRACTED by the journal Frontiers in Oncology on September 9, 2020. While this summary outlines the technical content presented, the findings should be viewed with caution as the scientific community has flagged issues with the original publication.

Introduction: The Third Revolution in Oncology

Oncolytic Virotherapy is often described as the "third revolution" in cancer treatment. Unlike traditional therapies that can be limited by systemic toxicity and drug resistance, OVs exploit the natural defects in cancer cell antiviral signaling—such as impaired Type I interferon pathways—to replicate selectively within tumors. This approach aims for high killing efficiency with precise targeting and minimal side effects.

Mechanism of Action: Turning "Cold" Tumors "Hot"

OVs act as a dual-threat approach. Beyond direct cell lysis (physical destruction of the cancer cell), they serve as potent "immune primers." When a cancer cell is lysed, it releases Damage-Associated Molecular Patterns (DAMPs) and tumor-derived antigens. This process effectively "unmasks" the tumor, allowing the host's immune system to recognize and attack distant, uninfected metastatic sites.

Figure 1: The anticancer mechanism of oncolytic viruses, illustrating cell lysis and the subsequent immune recognition at distant metastasis sites.

To overcome the body's natural tendency to neutralize viruses before they reach the tumor, researchers are exploring "Trojan Horse" delivery systems. These involve using carrier cells, such as stem cells or Cytokine-Induced Killer (CIK) cells, to shield the virus during systemic circulation.

Diagnostic Potential (Theranostics)

OVs are also being developed as diagnostic tools. By inserting reporter genes—such as Luciferase, Green Fluorescent Protein (GFP), or the human sodium-iodine symporter (hNIS) gene—into the viral genome, clinicians can visualize tumor margins and small metastases in real-time using PET, SPECT, or MRI. For example, OVs expressing the hNIS gene have successfully allowed for the detection of gastric cancer metastases that were otherwise invisible to standard CT scans.

Clinical Landscape and Efficacy

The paper synthesizes data from numerous clinical trials, highlighting several major products currently in use or under investigation. Key results include:

  • Oncorine (H101): In trials for head and neck cancer, combining Oncorine with chemotherapy resulted in a 78.8% response rate, compared to 39.6% for chemotherapy alone.
  • T-VEC (Imlygic): The first FDA-approved OV, showing a 26% overall response rate in advanced melanoma.
  • Rigvir: Retrospective studies suggest improved survival rates for early-stage melanoma patients in Latvia when used post-surgery.
Table 3: Summary of clinical trials for various oncolytic viruses, including efficacy and common side effects like flu-like symptoms.

Challenges and Future Directions

Despite the potential, several hurdles remain. The innate and adaptive immune systems frequently clear the virus before it can reach the target site, especially during intravenous delivery. Furthermore, there are biosafety concerns regarding the use of live viruses in immunocompromised patients.

The retraction of this specific article underscores the need for continued, rigorous research. Future work must focus on large-scale, reproducible Phase III trials and the optimization of combination strategies—particularly pairing OVs with checkpoint inhibitors to increase T-cell infiltration in non-responsive patients.

Summary updated

Abstract

Cancer has always been an enormous threat to human health and survival. Surgery, radiotherapy, and chemotherapy could improve the survival of cancer patients, but most patients with advanced cancer usually have a poor survival or could not afford the high cost of chemotherapy. The emergence of oncolytic viruses provided a new strategy for us to alleviate or even cure malignant tumors. An oncolytic virus can be described as a genetically engineered or naturally existing virus that can selectively replicate in cancer cells and then kill them without damaging the healthy cells. There have been many kinds of oncolytic viruses, such as herpes simplex virus, adenovirus, and Coxsackievirus. Moreover, they have different clinical applications in cancer treatment. This review focused on the clinical application of oncolytic virus and predicted the prospect by analyzing the advantages and disadvantages of oncolytic virotherapy.
BibTeX
@inproceedings{cao2020retracted,
  author = {Guodong Cao and Xiaobo He and Qiang Sun and Sihan Chen and Ke Wan and Xin Xu and Xudong Feng and Pengping Li and Qing Chen and Maoming Xiong},
  title = {{RETRACTED: The Oncolytic Virus in Cancer Diagnosis and Treatment}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.01786},
}

Loading related content...

Figure